医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EuBiologics: Phase III Clinical Trial IND Approval of EuCorVac-19, COVID-19 Vaccine Candidate, in South Korea

2022年02月03日 PM11:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi), a South Korean biotech company, announced on Jan 28th that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, obtained approval to conduct Phase III comparison clinical trials (Phase III IND Approval) from the Ministry of Food and Drug Safety in South Korea.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220203005421/en/

EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, obtained approval to conduct Phase III comparison clinical trials (Phase III IND Approval) from the Ministry of Food and Drug Safety in South Korea (Photo: Business Wire)

EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, obtained approval to conduct Phase III comparison clinical trials (Phase III IND Approval) from the Ministry of Food and Drug Safety in South Korea (Photo: Business Wire)

Eubiologics is able to commence Phase III comparison trial for 4,000 healthy participants including the Philippines, Bangladesh and other countries based on the standard comparison clinical trial guideline by the Ministry of Food and Drug Safety in Korea.

Eubiologics will work closely with the global CROs for recruiting the participants to expedite the entire process in low vaccination rate countries and will also expedite the trial result analysis to advance EuCorVac-19’s regulatory approval and commercialization.

Eubiologics is developing EuCorVac-19, its vaccine platform, which consists of owned antigen, EulMT in-licensed from Korea Institute of Science and Technology and SNAP technology of POP Biotechnologies that EuBiologics has invested. The company has announced Phase I/II trial interim results in December 2021.

On the other hand, as EuCorVac-19 has already proved its safety and efficacy through Phase I/II clinical trial, the company expects to expedite the development of Omicron variant vaccine based on the same platform used for EuCorVac-19. Currently, the pre-clinical trial of Mouse immunogenicity test and TG mouse which is transformed from human gene are under progress and the company plans to proceed with the human trial within the 1st half of 2022. In addition, a booster vaccine is necessary due to the dominance of the Omicron variant, and thus the company will commence its trial to prove efficacy as a booster vaccine.

Eubiologics has 2 main animal-based bioreactors (1,000L) to produce recombinant protein antigens at Chuncheon Plant 1 and EcML which is adjuvant at Chuncheon Plant 2. The total capacity of COVID-19 vaccine is from 100M to 200M doses per year. EuCorVac-19 vaccine uses the same type of cell line which is for antibody treatment, so if the company uses these facilities, its manufacturing capacity can be further expanded.

A company official said, “The company has already had product supply MOUs with partners in the Philippines and Saudi Arabia, and many Asian, CIS, Latin American partners have shown a great interest in EuCorVac-19. Once the product is launched, the company will target the overseas markets that have high population and middle-income based on the product’s safety, efficacy and logistics convenience.”

Eubiologics has already received funds for Phase I/II (9.4billion KRW) March 2021 from the new drug development committee of the Ministry of Health and Welfare in Korea and recently submitted the application for phase III trial to get additional financial assistance.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005421/en/

CONTACT

EuBiologics Co., Ltd.

Tae Young Jin

+82-70-4881-7117

yjtae@eubiologics.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June
  • IntelliCentrics Seeks Strategic Alliance With Taiwanese Health Insurance Providers to Serve Millions of Taiwanese Patients Ensuring They Have Remote Access to Trusted, High Quality Healthcare.
  • 中智全球寻求与台湾医疗保险公司结成战略联盟,为数百万台湾患者提供服务,确保他们能够远程获得可靠及优质的医疗保健服务。
  • Sermo调查显示,今年ASCO的与会肿瘤学家对新的肺癌和乳腺癌研究最感兴趣
  • 訂正・差し替え SCAI 2022 Scientific Meeting で心原性ショックの予後改善に向けた Impella の研究と進歩を大きく紹介